You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

169 Results
Le test de dépistage du cancer du col de l’utérus recherche les types de virus du papillome humain (VPH) qui peuvent parfois provoquer un cancer du...
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    enzalutamide - For the treatment of metastatic castrate-resistant prostate cancer (mCRPC), with specific clinical criteria
Exceptional Access Program
    enzalutamide - For the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC), with specific clinical criteria
Exceptional Access Program
    enzalutamide - For the treatment metastatic castration sensitive prostate cancer (mCSPC), with specific clinical criteria
Apr 2025
Guidelines and Advice
Status: Current
ID: GL 20-2
Version: 2
Updated
Apr 2025
Guidelines and Advice
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab Deruxtecan - Unresectable Locally Advanced or Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab Deruxtecan - HER2-low Unresectable Locally Advanced or Metastatic Breast Cancer
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
May 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab Deruxtecan - Previously Treated Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
May 2025
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
May 2025

Pages